Evaluation of Treatment Response and Quality of Life of Esomeprazole for Reflux Esophagitis Patients
- Conditions
- Reflux Esophagitis
- Registration Number
- JPRN-UMIN000014449
- Lead Sponsor
- agoya University Graduate School of Medicine, Department of Gastroentelorogy and Hepatology
- Brief Summary
Because of the difficulty for gathering a new registration, we unfortunately decided to discontinue this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Not provided
1,Patients with a history of hypersensitivity to the study drug. 2,Patients in the administration of atazanavir sulfate or a Rirupibirin hydrochloride. 3,Patients with confirmed gastric ulcer, duodenal ulcer by endoscopy. 4,Patients who have unstable merger liver, kidney, heart disease or serious medical conditions. 5,History of gastrointestinal tract resection or vagotomy. 6,Pregnancy and lactation. 7,Patients treated with esomeprazole 14 days before obtaining informed consent 8,Patient in need of administration of the following agents other than the study drug during the study period (Excluding test drug), histamine H2-receptor antagonist, prokinetics, gastric mucosal protection, anticholinergic drugs, antacids, antidepressants, anti-anxiety drugs, steroids, bisphosphonates. 9,Patients who judged unsuitable for research participation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method